Flumatinib - CML - Chronic Myeloid Leukemia
Flumatinib (FM), a derivative of imatinib (IM), is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI).
VIDEOS
coming soon
coming soon
ARTICLES
New Drug for Chronic Myeloid Leukemia Might Stimulate the Market
January 2021, Clinical Cancer Research
Could Flumatinib Replace Gleevec in Chronic-Phase Chronic Myeloid Leukemia?
August 31,2019, CancerConnect
Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia
June 2, 2019, Cancer Therapy Advisor
Flumatinib Superior to Imatinib in Chronic Myeloid Leukemia
June 1, 2019, ASH Clinicals News
Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study
June 1, 2019, ASCO 2019
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants
January 4, 2014, NCBI
New Drug for Chronic Myeloid Leukemia Might Stimulate the Market
January 2021, Clinical Cancer Research
Could Flumatinib Replace Gleevec in Chronic-Phase Chronic Myeloid Leukemia?
August 31,2019, CancerConnect
Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia
June 2, 2019, Cancer Therapy Advisor
Flumatinib Superior to Imatinib in Chronic Myeloid Leukemia
June 1, 2019, ASH Clinicals News
Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study
June 1, 2019, ASCO 2019
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants
January 4, 2014, NCBI